Research News

There is no effective vaccine currently available to prevent Lyme disease in humans.

Experts from academia, government, and industry convened at Cold Spring Harbor Laboratory's Banbury Center to tackle this public health challenge. Now, a new paper published in the October 17 2019 issue of Clinical Infectious Diseases highlights the conference discussions, reiterates the need to stop the infection, and defines a strategy for developing effective vaccines.

Young adults who suffer from posttraumatic stress disorder (PTSD) may be more likely to experience a transient ischemic attack (TIA) or major stroke event by middle age, raising the risk as much as other better-known risk factors, according to new research published in Stroke, a journal of the American Stroke Association, a division of the American Heart Association.

The more medications a patient takes, the greater the likelihood that interactions between those drugs could trigger negative side effects, including long-term organ damage and even death. Now, researchers at Penn State have developed a machine learning system that may be able to warn doctors and patients about possible negative side effects that might occur when drugs are mixed.

Understanding the mechanisms that mediate widespread DNA damage in the cancer genome is of great interest to cancer physicians and scientists because it may lead to improved treatments and diagnosis.

In this study, a multi-institutional team led by researchers at Baylor College of Medicine has brought attention to genomic structural variation as a previously unappreciated mechanism involved in altering DNA methylation, a form of gene control, in human cancers.

New evidence from a WHO-led study, published in the Lancet, shows that more than one-third of women in four lower-income countries experienced mistreatment during childbirth in health facilities. Younger, less-educated women were found to be the most at risk of mistreatment, which can include physical and verbal abuse, stigmatization and discrimination, medical procedures conducted without their consent, use of force during procedures, and abandonment or neglect by health care workers.

A UK wide collaboration led by the University of Exeter, Royal Devon & Exeter NHS Foundation Trust and the Wellcome Sanger Institute, has demonstrated that a genetic variant carried by 40% of the population explains why some patients develop antibodies against the anti-TNF drugs, infliximab and adalimumab and lose response. The authors conclude that a further trial is required to confirm that genetic testing prior to treatment will reduce the rate of treatment failure by facilitating the most effective choice of therapy for individual patients. The research, part-funded by Wellcome, Crohn’s & Colitis UK, Guts UK, Cure Crohn’s Colitis and supported by the NIHR, is part of a programme of work committed to finding the right drug for the right patient first time.

Many drugs, especially those made of proteins, cannot be taken orally because they are broken down in the gastrointestinal tract before they can take effect. One example is insulin, which patients with diabetes have to inject daily or even more frequently.

In 2015, EPFL researchers led by Melanie Blokesch published a seminal paper in Science showing that the bacterium responsible for cholera, Vibrio cholerae, uses a spring-loaded spear to literally stab neighboring bacteria and steal their DNA. They identified the spear mechanism to be the so-called “type VI secretion system” or T6SS, also used for interbacterial competition by many other bacteria.

Biomedical engineers at Duke University have developed a method to address failures in a promising anti-cancer drug, bringing together tools from genome engineering, protein engineering and biomaterials science to improve the efficacy, accuracy and longevity of certain cancer therapies. 

To spur innovation to meet the challenges of complex care management for people with Alzheimer’s disease and related dementias (AD/ADRD) and their families, the National Institute on Aging (NIA), part of the National Institutes of Health, has funded a new effort designed to test care interventions in real-world settings.

To spur innovation to meet the challenges of complex care management for people with Alzheimer’s disease and related dementias (AD/ADRD) and their families, the National Institute on Aging (NIA), part of the National Institutes of Health, has funded a new effort designed to test care interventions in real-world settings.  Brown University, Providence, Rhode Island, will partner with Hebrew Senior Life, a Harvard Medical School Affiliate, Roslindale, Massachusetts, to manage the Imbedded Pragmatic AD/ADRD Clinical Trials (IMPACT) Collaboratory with funding from NIA that is expected to total $53.4 million over five years. IMPACT Collaboratory researchers will team with scientists at other universities with health care and long-term care systems to guide research to develop and test novel ways to care for people with AD/ADRD.